Mimedx (MDXG) Asset Utilization Ratio (2011 - 2026)

Mimedx (MDXG) posted Asset Utilization Ratio of 1.2 for Q2 2026, up 0.74% sequentially from 1.2 in Q1 2026, and down 7.02% YoY from 1.3 in Q2 2025.

Mimedx (MDXG) Asset Utilization Ratio (2011 - 2026) Analysis & Trends

Mimedx has reported Asset Utilization Ratio for 15 years, with the latest figure at 1.2 in Q2 2026.

Quarterly Asset Utilization Ratio fell 7.02% year-over-year to 1.2 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 1.2 (down 7.02% YoY) and the FY2025 annual result came in at 1.38, down 0.5% from the prior year.
Asset Utilization Ratio rose to 1.2 in Q2 2026 per MDXG's latest filing, from 1.2 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 1.71 in Q2 2023 and troughed at 1.2 in Q1 2026.
A 5-year average of 1.42 and a median of 1.41 in 2022 frame the typical range for Asset Utilization Ratio.
The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio rose 24.28% in 2023, then retreated 14.5% in 2024.
Over 5 years, Asset Utilization Ratio stood at 1.56 in 2022, then decreased by 3.48% to 1.5 in 2023, then retreated by 8.52% to 1.37 in 2024, then decreased by 7.91% to 1.27 in 2025, then retreated by 4.8% to 1.2 in 2026.
According to Business Quant data, Asset Utilization Ratio over the past three periods registered 1.2, 1.2, and 1.27 for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.38
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.69
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	186.67
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.13
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.90
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.54
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn	1.20

Download Data